AppLovin stock price slides as short-seller fight and Fed jitters weigh on APP shares
30 January 2026
1 min read

AppLovin stock price slides as short-seller fight and Fed jitters weigh on APP shares

New York, Jan 30, 2026, 11:54 AM (ET) — Regular session

  • AppLovin shares dropped in late morning trading as investors pared back exposure to tech-related stocks.
  • Traders zeroed in on the company’s reaction to a recent short-seller report.
  • Coming next: AppLovin’s quarterly earnings and guidance, set to drop after the close in mid-February.

AppLovin Corp shares dropped 11.3%, slipping to $504.80 in late morning trading on Friday, after hitting a session low of $495.23. The Nasdaq-listed stock fell $64.44 from its previous close.

The sell-off follows AppLovin’s pushback against a short-seller report from CapitalWatch. The company issued a cease-and-desist letter, labeling the report “defamatory and baseless” and calling its claims “absurd and demonstrably false,” CNBC reports. Short sellers typically publish negative research while wagering that the stock will decline. 1

AppLovin plans to release its fourth-quarter and full-year 2025 results on Feb. 11, right after the U.S. market closes, the company said. Management will hold a webcast that same day. 2

Macro headwinds weighed on U.S. stocks, which dipped following President Donald Trump’s nomination of former Fed Governor Kevin Warsh to head the central bank. On top of that, producer prices came in hotter than anticipated, according to a Reuters report. “There is a general sense of hawkishness in the market,” noted Swissquote Bank senior analyst Ipek Ozkardeskaya. 3

Software stocks showed vulnerability on Thursday. SAP and ServiceNow dropped following updates that stirred fresh concern over AI tools potentially cutting into demand for subscription software, or SaaS, Reuters reported. “Pricing a worst-case scenario that software is dead,” said Adam Turnquist, chief technical strategist at LPL Financial. 4

AppLovin stands right where these trends converge: software stocks sensitive to rate shifts and advertising spend that can shrink quickly when caution sets in. When sentiment shifts bearish, high-growth firms often get hammered before anyone digs deeper.

AppLovin’s stock remains comfortably above its 52-week low but has slipped significantly from its peak. According to MarketBeat, the 52-week range spans $200.50 to $745.61; as of Friday, the share price sat roughly 32% below that top mark. 5

The downside scenario is straightforward. If the short-seller controversy drags on, it could continuously weigh on positioning. Any hint of weaker ad demand or cautious guidance would only intensify the pressure.

The tone would shift if the numbers were cleaner, the outlook steadier, and management offered a clear distinction between noise and signal. Investors, meanwhile, must brace for whatever unfolds next in rates and risk appetite.

Eyes will be on Feb. 11, as AppLovin releases its earnings after the bell. Beyond the headline numbers, traders want to hear the company’s guidance and any response to the short-seller claims.

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Freeport-McMoRan stock sinks as copper’s record rally snaps back — what traders watch next
Previous Story

Freeport-McMoRan stock sinks as copper’s record rally snaps back — what traders watch next

Robinhood stock rises on report it could run new ‘Trump accounts’ for kids
Next Story

Robinhood stock rises on report it could run new ‘Trump accounts’ for kids

Go toTop